Wyeth to close Premarin plant, declining sales to blame

Share this article:
Wyeth said that it plans to cease operations at its Premarin (conjugated estrogens tablets) manufacturing plant in Rouses Point, N.Y., because of declining sales of the hormone-replacement drug.
In a news release, Wyeth said it plans to phase out manufacturing at the plant and halt all operations by late 2008. Staff reductions will begin in 2006 and extend over the next three years.
Sales of post-menopausal hormone therapies have been significantly hurt by studies showing women who take hormones after menopause have a greater risk of breast cancer, stroke, heart attack, incontinence and dementia.
A Wyeth spokesman told The Wall Street Journal the plant employs 1,200 workers.
 The spokesman couldn't immediately estimate the number of workers expected to leave the company or the anticipated costs of the move, according to the Journal report. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.